A daily pill called daraxonrasib combined with chemotherapy has shown positive results in treating advanced pancreatic cancer, according to clinical trial findings presented on Friday.

The combination therapy was assessed in 61 individuals with advanced pancreatic cancer that had metastasised elsewhere in the system. Tumours shrank or disappeared in 60.7 per cent of the patients treated during the study.

Scans revealed no detectable signs of cancer in approximately one in 12 patients, accounting for 8.2 per cent of the participants.

Pancreatic cancer is one of the most aggressive forms of cancer and carries high mortality rates. Chemotherapy remains a standard treatment option for advanced stages of the disease when it has metastasised.

Clinical trials serve as essential research studies designed to evaluate the safety and efficacy of novel medical therapies.